A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients

Clinical Therapeutics

Volumn 20, Issue 3, 1998, Pages 505-516

  Reimherr, Frederick W ^a   Cunningham, Lynn A ^b   Batey, Sharyn R ^c   Johnston, J Andrew ^c   Ascher, John A ^c  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b Clinical Research Associates   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Antidepressants; Bupropion; Depression; Sustained release

Indexed keywords

AMFEBUTAMONE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; STATISTICAL ANALYSIS; SUSTAINED RELEASE PREPARATION;

EID: 0031926296     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80060-X     Document Type: Article

References (39)

1. Regier D, Boyd JH, Burke JD, et al. Onemonth prevalence of mental disorders in the United States: Based on five epidemiologic catchment area sites. Arch Gen Psychiatry. 1988;45:977-986.
2. Montano CB. Recognition and treatment of depression in a primary care setting. J Clin Psychiatry. 1994;55(Suppl): 18-34.
3. Stokes PE, A primary care perspective on management of acute and long-term depression. J Clin Psychiatry. 1993;54(Suppl): 74-84.
4. Fabre LF, Brodie KH, Garver D, Zung WWK. A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients. J Clin Psychiatry. 1983; 44:88-94.
5. Feighner JP, Gardner EA, Johnston JA, et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry. 1991;52:329-335.
6. Feighner J, Hendrickson G, Miller L, Stern W. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder. J Clin Psychopharmacol. 1986;6:27-32.
7. Lineberry CG, Johnston JA, Raymond RN, et al. A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. J Clin Psychiatry. 1990;51:194-199.
8. Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol. 1994;14: 170-179.
9. Ascher JA, Cole JO, Colin J, et al. Bupropion: A review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56:395-401.
10. Ferris RM, Cooper BR. Mechanism of antidepressant activity of bupropion. J Clin Psychiatry Monograph. 1993;11:2-14.
11. Preskorn SH, Burke M. Somatic therapy for major depressive disorder: Selection of an antidepressant. J Clin Psychiatry. 1992;53(Suppl 9):5-18.
12. Van Wyck Fleet J, Manberg PJ, Miller LL, et al. Overview of clinically significant adverse reactions to bupropion. J Clin Psychiatry. 1983;44:191-196.
13. Zung WWK, Brodie HKH, Fabre L, et al. Comparative efficacy and safety of bupropion and placebo in the treatment of depression. Psychopharmacology. 1983;79: 343-347.
14. Bupropion (Wellbutrin SR®) product information. Glaxo Wellcome Inc., Research Triangle Park, North Carolina, 1996.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed., revised. Washington, DC: American Psychiatric Association: 1987;228-230.
16. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56-62.
17. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1968;6:278-296.
18. Guy W. ECDEU Assessment Manual for Psychopharmacology. DHEW Publication No. 76-338. Rockville, Md: National Institute of Mental Health, 1976;217-222.
19. Kavoussi RJ, Segraves RT, Hughes AR, et al. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry. 1997;58:532-537.
20. Keller MG, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: A 5-year prospective survey of 431 subjects. Arch Gen Psychiatry. 1992;49:809-816.
21. Greenberg RN. Overview of patient compliance with medication dosing: A literature review. Clin Ther. 1984;6:592-599.
22. Becker MH, Maiman LA. Strategies for enhancing patient compliance. J Community Health. 1980;6:113-135.
23. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;261:3273-3277.
24. Feighner JP, Meredith CH, Stern WC, et al. A double-blind study of bupropion and placebo in depression. Am J Psychiatry. 1984;141:525-529.
25. Halaris AE, Stern WC, Van Wyck Fleet J, Reno RM. Evaluation of the safety and efficacy of bupropion in depression. J Clin Psychiatry. 1983;44:101-103.
26. Pitts WM, Fann WE, Halaris AE, et al. Bupropion in depression: A tri-center placebo-controlled study. J Clin Psychiatry. 1983:44:95-100.
27. Branconnier RJ, Cole JO, Ghazvinian S, et al. Clinical pharmacology of bupropion and imipramine in elderly depressives. J Clin Psychiatry. 1983;44:130-133.
28. Chouinard G. Bupropion and amitriptyline in the treatment of depressed patients. J Clin Psychiatry. 1983;44:121-129.
29. Mendels J. Amin MM, Chouinard G, et al. A comparative study of bupropion and amitriptyline in depressed outpatients. J Clin Psychiatry. 1983;44:118-120.
30. Othmer E, Othmer SC, Stern WC, Van Wyck Fleet J. Long-term efficacy and safety of bupropion. J Clin Psychiatry. 1983;44:153-156.
31. Wenger TL, Stern WC. The cardiovascular profile of bupropion. J Clin Psychiatry. 1983;44:176-182.
32. Zung WWK. Review of placebo-controlled trials with bupropion. J Clin Psychiatry. 1983;44:104-114.
33. Gardner EA, Johnston JA. Bupropionan antidepressant without sexual patho-physiological action. J Clin Psychopharmacol. 1985;5:24-29.
34. Nemeroff CB. Evolutionary trends in the pharmacotherapeutic management of depression. J Clin Psychiatry. 1994;55(Suppl 12):3-15.
35. Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry. 1993;54: 459-465.
36. Segraves RT. Overview of sexual dysfunction complicating the treatment of depression. J Clin Psychiatry Monograph. 1992;10:4-10.
37. Meston CM, Gorzalka BB. Psychoactive drugs and human sexual behavior: The role of serotonergic activity. J Psychoact Drugs. 1992;24:1-40.
38. Harto-Truax N, Stern WC, Miller LL, et al. Effects of bupropion on body weight. J Clin Psychiatry. 1983;44:183-186.
39. Gardner EA. Management of the depressed patient: The art and science of compliance. Part IV: Patient compliance in antidepressant treatment. J Clin Psychiatry Monograph. 1982;5:19.